Insiders at Hillman Solutions selling shares without corresponding purchases may suggest they believe the shares are not undervalued. The significant but not outstanding insider ownership indicates a cautious outlook for the stock.
Hillman Solutions is undervalued, presenting a potential opportunity to buy more HLMN stock. Its future outlook isn't fully reflected in the current price. Consider other factors like balance sheet strength before investing.
Hillman Solutions insiders have shown optimism, refraining from selling shares but making substantial purchases, even at prices higher than current. Their actions indicate confidence in the company's future, despite no recent trades.
Upgrades •$飛塔信息(FTNT.US)$: BMO Capital Upgrades to Outperform from Market Perform - PT $350 (from $325) •$微芯科技(MCHP.US)$: Stifel Upgrades to Buy from Hold - PT $75 (from $70) •$Ovintiv(OVV.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $64 (from $56) •$Riot Platforms(RIOT.US)$: Compass Point Upgrades to Buy from Neutral - PT $14 (from $30) •$Snowflake(SNOW.US)$: Jefferies Upgrades to Buy f...
Gainers: •$Antares Pharma(ATRS.US)$+48.7% (to be acquired by Halozyme (HALO) for $5.60 per share) •$Sierra Oncology(SRRA.US)$+37.9% (acquired by GSK for $55 per share) •$Amryt Pharma(AMYT.US)$+11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients) •$BriaCell Therapeutics(BCTX.US)$+6% (presents development details of...
Hillman Solutions股票討論區
• $飛塔信息(FTNT.US)$ : BMO Capital Upgrades to Outperform from Market Perform - PT $350 (from $325)
• $微芯科技(MCHP.US)$ : Stifel Upgrades to Buy from Hold - PT $75 (from $70)
• $Ovintiv(OVV.US)$ : JPMorgan Upgrades to Overweight from Neutral - PT $64 (from $56)
• $Riot Platforms(RIOT.US)$ : Compass Point Upgrades to Buy from Neutral - PT $14 (from $30)
• $Snowflake(SNOW.US)$ : Jefferies Upgrades to Buy f...
• $美國航空(AAL.US)$ : JP Morgan Upgrades to Neutral From Underweight - PT $26 (from $18)
• $The AZEK(AZEK.US)$ : Citigroup Upgrades to Buy from Neutral - PT $30 (from $36)
• $波士頓物產(BXP.US)$ : Mizuho Upgrades to Buy from Neutral - PT $135 (from $120)
• $陶氏化學(DOW.US)$ : Citigroup Upgrades To Buy From Neutral - PT $82 (from $70)
• $克羅格(KR.US)$ : Exane Upgrades to Neutral from Underperform - PT $60
• $Milestone Pharmaceuticals(MIST.US)$ : Piper S...
• $Antares Pharma(ATRS.US)$ +48.7% (to be acquired by Halozyme (HALO) for $5.60 per share)
• $Sierra Oncology(SRRA.US)$ +37.9% (acquired by GSK for $55 per share)
• $Amryt Pharma(AMYT.US)$ +11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients)
• $BriaCell Therapeutics(BCTX.US)$ +6% (presents development details of...
暫無評論